ARQT vs. S

Last updated Apr 2, 2026

Compare and contrast key facts about Arcutis Biotherapeutics, Inc. (ARQT) and SentinelOne, Inc. (S).

Performance

ARQT vs. S - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcutis Biotherapeutics, Inc. (ARQT) and SentinelOne, Inc. (S). The values are adjusted to include any dividend payments, if applicable.

ARQT vs. S - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
ARQT Arcutis Biotherapeutics, Inc.	-17.01%	108.47%	331.27%	-78.18%	-28.64%	-24.00%
S SentinelOne, Inc.	-11.27%	-32.43%	-19.10%	88.07%	-71.10%	18.80%

Fundamentals

Market Cap ARQT : $3.27B S : $4.46B
EPS ARQT : -$0.12 S : -$1.36
PS Ratio ARQT : 8.45 S : 4.41
PB Ratio ARQT : 17.25 S : 3.10
Total Revenue (TTM) ARQT : $376.07M S : $1.00B
Gross Profit (TTM) ARQT : $339.38M S : $742.10M
EBITDA (TTM) ARQT : -$1.11M S : -$270.33M

Returns By Period

In the year-to-date period, ARQT achieves a -17.01% return, which is significantly lower than S's -11.27% return.

ARQT

• 1D: 2.29%
• 1M: -2.67%
• YTD: -17.01%
• 6M: 21.96%
• 1Y: 60.88%
• 3Y*: 29.88%
• 5Y*: -4.12%
• 10Y*: —

S

• 1D: 3.34%
• 1M: 1.37%
• YTD: -11.27%
• 6M: -23.64%
• 1Y: -28.48%
• 3Y*: -6.65%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ARQT vs. S — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARQT

ARQT Risk / Return Rank: 72
ARQT Sharpe Ratio Rank: 74
ARQT Sortino Ratio Rank: 74
ARQT Omega Ratio Rank: 69
ARQT Calmar Ratio Rank: 72
ARQT Martin Ratio Rank: 72

S

S Risk / Return Rank: 16
S Sharpe Ratio Rank: 15
S Sortino Ratio Rank: 17
S Omega Ratio Rank: 17
S Calmar Ratio Rank: 17
S Martin Ratio Rank: 14

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARQT vs. S - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcutis Biotherapeutics, Inc. (ARQT) and SentinelOne, Inc. (S). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARQT	S	Difference
Sharpe ratio Return per unit of total volatility	1.02	-0.59	+1.61
Sortino ratio Return per unit of downside risk	1.85	-0.60	+2.45
Omega ratio Gain probability vs. loss probability	1.22	0.92	+0.29
Calmar ratio Return relative to maximum drawdown	1.69	-0.68	+2.37
Martin ratio Return relative to average drawdown	3.97	-1.31	+5.28
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARQT vs. S - Sharpe Ratio Comparison

The current ARQT Sharpe Ratio is 1.02, which is higher than the S Sharpe Ratio of -0.59. The chart below compares the historical Sharpe Ratios of ARQT and S, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ARQT	S	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.02	-0.59	+1.61
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.06	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.02	-0.34	+0.36

Correlation

The correlation between ARQT and S is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ARQT vs. S - Dividend Comparison

Neither ARQT nor S has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ARQT vs. S - Drawdown Comparison

The maximum ARQT drawdown since its inception was -95.02%, which is greater than S's maximum drawdown of -83.79%. Use the drawdown chart below to compare losses from any high point for ARQT and S.

Drawdown Indicators

	ARQT	S	Difference
Max Drawdown Largest peak-to-trough decline	-95.02%	-83.79%	-11.23%
Max Drawdown (1Y) Largest decline over 1 year	-31.99%	-39.18%	+7.19%
Max Drawdown (5Y) Largest decline over 5 years	-94.71%	—	—
Current Drawdown Current decline from peak	-34.83%	-82.56%	+47.73%
Average Drawdown Average peak-to-trough decline	-50.46%	-65.75%	+15.29%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.63%	20.38%	-6.75%

Volatility

ARQT vs. S - Volatility Comparison

Arcutis Biotherapeutics, Inc. (ARQT) and SentinelOne, Inc. (S) have volatilities of 15.32% and 15.49%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARQT	S	Difference
Volatility (1M) Calculated over the trailing 1-month period	15.32%	15.49%	-0.17%
Volatility (6M) Calculated over the trailing 6-month period	43.81%	34.01%	+9.80%
Volatility (1Y) Calculated over the trailing 1-year period	60.16%	48.63%	+11.53%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	71.95%	64.06%	+7.89%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.53%	64.06%	+13.47%

Financials

ARQT vs. S - Profitability Comparison

The chart below illustrates the profitability comparison between Arcutis Biotherapeutics, Inc. and SentinelOne, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ARQT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Arcutis Biotherapeutics, Inc. reported a gross profit of 117.82M and revenue of 129.50M. Therefore, the gross margin over that period was 91.0%.

S - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, SentinelOne, Inc. reported a gross profit of 196.83M and revenue of 271.15M. Therefore, the gross margin over that period was 72.6%.

ARQT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Arcutis Biotherapeutics, Inc. reported an operating income of 18.39M and revenue of 129.50M, resulting in an operating margin of 14.2%.

S - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, SentinelOne, Inc. reported an operating income of -79.90M and revenue of 271.15M, resulting in an operating margin of -29.5%.

ARQT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Arcutis Biotherapeutics, Inc. reported a net income of 17.40M and revenue of 129.50M, resulting in a net margin of 13.4%.

S - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, SentinelOne, Inc. reported a net income of -110.23M and revenue of 271.15M, resulting in a net margin of -40.7%.